South Korea rolled out regulatory changes designed to speed biosimilar development, including shorter review timelines, eased Phase III trial requirements, and simplified oversight of manufacturing changes. The reforms are intended to reduce time-to-market for biosimilars while maintaining review standards for quality and comparability. The policy update also targets operational complexity around manufacturing changes, aiming to make it easier for biosimilar developers to adjust processes without restarting extensive regulatory work. Companies are expected to reassess development plans for biosimilar candidates as the approval framework shifts. For regional competition, the change signals an ongoing push by regulators to balance faster access to lower-cost biologics with streamlined documentation and risk-based review elements.